Holds 2 valid CEPs for cyproterone, filing since 2017. Its 2024 FDA inspection closed as VAI, and its GMP is recognised in 22 markets.
Holds 4 valid CEPs for cyproterone, filing since 2025. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 34 markets.
Holds one active US DMF for cyproterone, filing since 2005. Its 2021 FDA inspection closed as VAI, and its GMP is recognised in 1 market.
Holds one valid CEP for cyproterone, filing since 2022.
Holds one valid CEP for cyproterone, filing since 2023. Its 2023 FDA inspection closed as VAI.
Registered with SFDA (Saudi Arabia) for cyproterone. Its 2025 FDA inspection closed as OAI, and its GMP is recognised in 2 markets.
The names are listed below. The filings, inspection history and GMP certificates behind each one are available with a free account.
Open the full list with a free accountContract manufacturers make to order rather than holding their own filing for this molecule.
The order is set by active filings weighted by regulator, inspection outcomes and their recency, breadth of GMP recognition, and evidence of real exports, less any open risk flags. Every factor appears on the card it produced. Read the full method.
Tell us which markets you need to file in. These suppliers come back tiered for those markets, with the price corridor and an RFI sheet.
Start for freeFixed-dose combinations containing cyproterone. Each page leads with the verified API makers of every component.